• ABPI Website
  • Media
  • ABPI cheers new gene therapy for IMF and innovative payment first

ABPI cheers new gene therapy for IMF and innovative payment first

NICE has recommended CSL Behring’s HEMGENIX® (etranacogene dezaparvovec) as the first single infusion gene therapy for adults with severe or moderately severe haemophilia B without a history of FIX inhibitors for reimbursement via a managed access agreement, recognising the treatment as cost-effective in England [1].

Responding to the news, Paul Catchpole, Director of Value and Access policy, said:

This announcement is positive news for eligible patients with haemophilia B, as well as the wider gene therapy community, which is striving to bring these highly innovative treatments to patients.

“It marks the first time a medicine has been granted managed access through the Innovative Medicines Fund since it was launched in 2022. We hope we will see more new medicines reaching patients through this pathway in the future”.

“It is also encouraging to see an innovative payment model has been agreed, with payments potentially linked to how well the treatment performs over time. Looking at the new medicines pipeline, these payment models may become more important for some medicines in the years ahead.”


Last modified: 27 June 2024

Last reviewed: 27 June 2024

[1] CSL Behring, NICE recommends CSL Behring’s HEMGENIX®, 27 June 2024

The ABPI exists to make the UK the best place in the world to research, develop and use new medicines. We represent companies of all sizes who invest in discovering the medicines of the future. 

Our members supply cutting edge treatments that improve and save the lives of millions of people. We work in partnership with Government and the NHS so patients can get new treatments faster and the NHS can plan how much it spends on medicines. Every day, we partner with organisations in the life sciences community and beyond to transform lives across the UK.